GET DAILY SIGNALSFaeth Therapeutics (FTH) Stock Slides -48% in 30 Days: Examining the Post-Data Reaction
Key Takeaways
- Faeth Therapeutics (FTH) shares have fallen roughly 48% over the last 30 days, from about $20.00 in mid-October to approximately $10.31.
- The sharpest decline came after the company's November 9, 2026 Phase 2 PIK-201 data readout, which investors judged as falling short of expectations versus emerging antibody-drug conjugates.
- The longer three-month trend is even steeper, with shares down roughly 64% from mid-August levels amid pre-data de-risking and the post-data selloff.
- Several analysts called the selloff overdone, with BTIG, H.C. Wainwright, and Lucid Capital each reiterating Buy ratings and price targets well above the current share price.
- Faeth reported $174.8 million in cash, equivalents, and marketable securities as of September 30, 2026, providing runway for continued clinical development.
- The company plans to advance PIKTOR toward a Phase 3 registrational trial in advanced endometrial cancer, subject to regulatory alignment.
Faeth Therapeutics (FTH) Company Background
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's lead program is PIKTOR, an investigational, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor. Together, these agents are designed to block multiple nodes of the PI3K/AKT/mTOR (PAM) pathway at once, an approach intended to address the signaling feedback and resistance mechanisms that have historically limited single-node pathway inhibitors.
Faeth was formed through a reverse merger in which the former Sensei Biotherapeutics acquired Faeth and adopted the Faeth name and FTH ticker in June 2026. The company is headquartered in Austin, Texas, and is led by co-founder and Chief Executive Officer Anand Parikh. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer and a Phase 1b/2 trial in HR+/HER2- advanced breast cancer, with the PAM pathway dysregulated in up to an estimated 50% of all solid tumors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance: The -48% Drop Over 30 Days and Steeper Quarterly Trend
Over the last 30 days, FTH has declined approximately 48%, falling from a closing price of $20.00 on October 14, 2026 to roughly $10.31 in the latest session. The move was concentrated around a single event: on November 9, 2026, the stock tumbled more than 40% in one session after the company released preliminary Phase 2 data, and shares continued to drift lower in subsequent sessions.
The three-month trend is steeper still. From a closing price of about $28.55 in mid-August, shares are down roughly 64%. Within that window, the stock actually climbed to a 52-week high near $42 in early September before entering a multi-week slide that accelerated after the November data readout. The overall pattern reflects a sustained risk-off repricing in the lead-up to, and following, a pivotal clinical catalyst.
The November Data Readout and Investor Reaction
The dominant catalyst was the November 9, 2026 release of preliminary topline results from the Phase 2 PIK-201 trial, which evaluated PIKTOR combined with paclitaxel in patients with advanced endometrioid endometrial cancer. The data showed a confirmed objective response rate (ORR) of 33% in 36 efficacy-evaluable patients, a disease control rate of 83%, and a preliminary median progression-free survival of 7.4 months. Among patients with a PIK3CA mutation, the confirmed ORR was 44%.
Although the company described the results as supporting advancement into a Phase 3 registrational trial, investors interpreted the 33% headline ORR as broadly in line with — rather than clearly superior to — emerging antibody-drug conjugates, which triggered a sharp selloff. Analyst commentary pushed back on that reaction. BTIG maintained a Buy rating and $55 price target, H.C. Wainwright reiterated Buy with a $60 target, and Lucid Capital kept a Buy rating with a $59 target, with several firms describing the decline as overdone relative to the dataset. In my view, this reaction warrants closer scrutiny given the analyst pushback.
Quarterly Context and Broader Repricing
The quarterly decline reflects a broader repricing of the company's clinical positioning. After peaking near $42 in early September, shares began to give back gains as investors positioned ahead of the year-end Phase 2 readout. The company's third-quarter update, reported in early November, highlighted $174.8 million in cash and an FDA Fast Track designation for PIKTOR in advanced endometrial cancer, but these positive developments were overshadowed by growing uncertainty about how the eventual data would compare with competing regimens.
The November data release then crystallized that uncertainty. With the single-arm study unable to establish comparative efficacy against other available therapies, the market reset expectations for PIKTOR's differentiation. The multi-month slide is therefore best understood as a combination of pre-event de-risking and a post-event revaluation of the lead program's competitive profile.
Key Catalysts Ahead for FTH Investors
Looking ahead, the most important catalyst is the company's progress toward a Phase 3 registrational trial for PIKTOR in advanced endometrial cancer, which will depend on regulatory alignment with the FDA. Additional follow-up and analysis of the Phase 2 PIK-201 data may also refine the efficacy and safety picture. In 2027, interim Phase 1b/2 data from the HR+/HER2- advanced breast cancer study (FTH-PIK-101) represents another key readout.
Investors should also monitor cash runway and spending, analyst revisions, and the broader competitive landscape for PAM-pathway and antibody-drug conjugate therapies in endometrial cancer. As a clinical-stage company, Faeth's share price is likely to remain sensitive to clinical data, regulatory milestones, and financing decisions rather than near-term revenue fundamentals. I’m watching this closely for any updates on regulatory feedback.
AI Tools in My Research Process
In my own research, I often turn to Tickeron’s Trending AI Robots to explore how automated strategies are positioning around clinical-stage names like this one. The section highlights top-performing bots across strategies and timeframes, offering a practical starting point for evaluating systematic approaches without sifting through every option available. This helps me cross-check sentiment and positioning in a structured way.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
FTH in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 12, 2026
FTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 35 cases where FTH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTH advanced for three days, in 168 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTH as a result. In 86 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FTH turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for FTH entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.294) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement